Medindia

X

Concentric Medical Announces First Patients Treated With Trevo(TM) System in Acute Ischemic Stroke

Tuesday, January 12, 2010 Press Release J E 4
Advertisement


MOUNTAIN VIEW, Calif., Jan. 12 Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that the first cases have been performed using its Trevo(TM) System in Europe. The Trevo System is an innovative, high performing, easy-to-use thrombus retrieval system. The main component of the Trevo System is a stentriever(TM), a new generation of retrieval devices which removes clots that cause stroke.

A number of renowned interventionalists have used the Trevo System for their patients in the last few weeks at leading European stroke centers. Professor Tommy Andersson MD PhD, Head of Neurointervention at Karolinska University Hospital, Stockholm, Sweden, completed one of the first cases and said, "The new Trevo System was remarkably effective. The Trevo was also very easy to use - this is key in being able to rapidly restore blood flow for patients suffering an acute ischemic stroke. I believe the Trevo System may represent a great advance in the treatment of this potentially devastating condition."

Concentric Medical is the pioneer in developing devices for ischemic stroke intervention. Since 2004, Concentric Medical's devices have been used in thousands of stroke patients worldwide. This experience has been incorporated into the design of the Trevo System to make thrombus removal an easier, faster and more predictable procedure.

Maria Sainz, President and CEO of Concentric Medical, said, "The Trevo System represents a very exciting opportunity for Concentric, one that has the potential to greatly expand the treatment of stroke. As a leader in stroke intervention, we are committed to bringing innovative tools to clinicians. We are also committed to offering the broadest range of interventional devices and systems to treat patients effectively."

Concentric Medical currently markets the Merci RetrieverŪ, which is the market leading solution for ischemic stroke intervention. In addition, Concentric's DAC(TM) catheters are often used in the setting of ischemic stroke and other neurointerventional procedures. Together, the Trevo System, the Merci Retriever and the DAC family of catheters represent an unparalleled array of choices for physicians involved in the treatment of ischemic stroke.

About Concentric Medical

Concentric Medical is located in Mountain View, California and is the global leader in the endovascular treatment of acute ischemic stroke. The company manufactures and markets solutions for ischemic stroke: minimally invasive devices that are delivered into the brain to restore blood flow by removing blood clots that cause ischemic stroke. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies. For more information about Concentric Medical, please visit www.concentric-medical.com.

About Acute Ischemic Stroke

Stroke is the third leading cause of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain. In 2004 the FDA cleared Concentric Medical's Merci Retriever for use in patients who are ineligible for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device created a departure from the historic method of caring for stroke patients and offered physicians and patients a long-awaited option for stroke intervention.

Media Contact: Mike Dineen, VP of Marketing +1 650-938-2100 strokeinfo@concentric-medical.com

SOURCE Concentric Medical
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CEL-SCI Completes Validation of Manufacturing Faci...
S
QIAGEN Acquires ESE GmbH